CN116023391A - Deuterated piperidine amide CGRP inhibitor medicine and application thereof - Google Patents
Deuterated piperidine amide CGRP inhibitor medicine and application thereof Download PDFInfo
- Publication number
- CN116023391A CN116023391A CN202211601118.0A CN202211601118A CN116023391A CN 116023391 A CN116023391 A CN 116023391A CN 202211601118 A CN202211601118 A CN 202211601118A CN 116023391 A CN116023391 A CN 116023391A
- Authority
- CN
- China
- Prior art keywords
- cgrp
- deuterated
- pharmaceutically acceptable
- piperidine amide
- acceptable salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title claims abstract description 27
- 239000003112 inhibitor Substances 0.000 title claims abstract description 15
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical class NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title claims abstract 7
- 239000003814 drug Substances 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 13
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 7
- -1 deuterated piperidine amides Chemical class 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000027455 binding Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QHXLXUIZUCJRKV-UHFFFAOYSA-N 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound FC1=CC2=NN(C)C=C2C=C1C(F)(F)C(N1N=2)=NN=C1C=CC=2C(=C1)C=NN1C1CC1 QHXLXUIZUCJRKV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a deuterated piperidine amide CGRP inhibitor, which is shown in the following formula I:
Description
Technical Field
The invention belongs to the field of biological medicine, and in particular relates to a deuterated piperidine amide CGRP inhibitor medicine and application thereof.
Background
Migraine (migrain) is a common neurological disorder that can cause severe pain on one or both sides of the head, and the associated symptoms include nausea, vomiting, sensitivity to light, sound or smell. If left untreated, a single episode may last from 4 to 72 hours and may repeatedly occur, severely affecting the patient's work and life. The pathogenesis of migraine is not well defined, but is affected by environmental and genetic factors and is closely related to family history. Over 10 million people worldwide have migraine, which is one of the most serious cases of medical disability by the world health organization.
One leading hypothesis currently regarding the pathogenic mechanisms of migraine is based on the activation of the trigeminal vascular system. Several neuropeptides are involved in this activation, with Calcitonin Gene Related Peptide (CGRP) playing a key role. CGRP exerts a variety of different biological effects through the peripheral and Central Nervous System (CNS). Functional CGRP-receptor (CGRP-R) complexes have been well characterized and new therapeutic approaches target CGRP itself and its receptor.
For the medicine for treating migraine with good treatment effect, the medicines which are selected in the market are not many, so that the clinical requirement is high, and the search for a novel CGRP inhibitor for treating migraine is also an urgent task.
Disclosure of Invention
The invention provides a deuterated compound of a deuterated piperidine amide CGRP inhibitor and pharmaceutically acceptable salts thereof, which can further improve the pharmacokinetic properties of the deuterated compound of the piperidine amide CGRP inhibitor and pharmaceutically acceptable salts thereof, and reduce the administration dosage and possible toxic and side effects.
In order to achieve the above object, the present invention provides a deuterated compound of a piperidine amide CGRP inhibitor according to the following formula I:
the deuterated compound of the piperidine amide CGRP inhibitor and the pharmaceutically acceptable salt thereof are selected from methanesulfonate, maleate, hydrochloride or phosphate.
The deuterated compound and the pharmaceutically acceptable salt thereof disclosed by the invention comprise the application of the deuterated compound in preparation of antitumor drugs.
The deuterated compound and the pharmaceutically acceptable salt thereof provided by the invention comprise the deuterated compound and the pharmaceutically acceptable salt thereof as active ingredients and pharmaceutically acceptable carriers.
The deuterated compound and the pharmaceutical composition of the pharmaceutically acceptable salt thereof are selected from capsules, powder, tablets, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories or patches. The beneficial effects are that: compared with the prior art, the invention has the following advantages:
the invention provides a deuterated piperidine amide CGRP inhibitor drug which has excellent CGRP protein binding activity and CGRP-antagonistic activity, and can further improve the pharmacokinetic properties of the piperidine amide CGRP inhibitor and reduce the dosage and possible toxic and side effects.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Example 1: synthesis of Compound I
The synthetic route for compound I is as follows:
intermediate 1 can be prepared by the process of patent CN 108473465;
to a solution of intermediate 1 (0.5 mmol) in N, N-dimethylformamide (10 mL) was added potassium hydroxide (2 mmol,4 eq) and elemental iodine (1 mmol,2 eq), reacted for 3 hours at room temperature, monitored by TLC for completion of the reaction, quenched by addition of saturated sodium sulfite solution, extracted with ethyl acetate (10 mL x 2) in the aqueous phase, washed with water (20 mL x 2), dried over anhydrous sodium sulfate in saturated brine (20 mL) and concentrated column chromatography to give intermediate 2.
Sodium acetate (1 mmol,2 eq) was added to deuterated acetic acid solution (8 mL) of intermediate 2 (0.5 mmol), the reaction was completed for 2 hours, room temperature was allowed to react for 24 hours, TLC detection was complete, and concentration under reduced pressure and column chromatography were performed to obtain intermediate 3 compound.
Intermediate 3 (3 mmol) and DSC (3.3 mmol) were dissolved in DMF (20 mL), triethylamine (12 mmol) was added and stirred at room temperature for half an hour, then intermediate 4 was added in portions and stirring continued at room temperature overnight, TLC detection of reaction completion. Water was added, extraction was performed using ethyl acetate, the organic phase was collected, concentrated, and column chromatography was performed to obtain intermediate 5.
Intermediate 6 can be prepared by the method of patent CN 108473465;
intermediate 5 (3 mmol) was dissolved in DMF (20 mL), HATU (4 mmol) was added and after half an hour stirring, intermediate 6 (3 mmol) and DIPEA (6 mmol) were added and the reaction continued overnight, TLC detection of reaction completion, filtration, washing of the solid with water and drying to give example 1. 1 H NMR(500MHz，Chloroform-d)δ8.33(dd，J＝3.5，2.2Hz，1H)，8.31-8.17(m，3H)，7.81(d，J＝9.1Hz，1H)，7.73(d，J＝9.3Hz，1H)，7.50(d，J＝2.2Hz，1H)，7.23-7.10(m，2H)，6.80-6.56(m，2H)，4.59(p，J＝4.1Hz，1H)，4.45(dt，J＝9.3，7.7Hz，1H)，4.38(dt，J＝9.2，6.8Hz，1H)，3.57-3.35(m，12H)，2.99-2.83(m，2H)，2.69(s，3H)，2.62(td，J＝5.3，4.1Hz，4H)，2.52-2.43(m，4H)，1.89-1.72(m，3H)，1.66-1.48(m，4H).
Test example 1: CGRP binding Activity assay
The compound was dissolved in DMSO at a concentration of 100mM, diluted with 10mM HEPES (20 mM NaCl, pH 8.5) buffer, and diluted 2-fold to prepare 16 concentration gradients. The prepared concentration gradient sample and the dye-labeled CGRP protein are mixed according to the proportion of 1:1, incubated at room temperature and in dark for 10min, the sample is loaded to Monolith NT.115, tested by using a Nano Temper Monolith NT.115 interaction analyzer, and the KD value of the compound is calculated by Nano template software.
| Compounds of formula (I) | Kd(nM) |
| Example 1 Compounds | 1.2 |
| BHV-3100 | 9.5 |
From the table above, compared with the positive drug BHV3100, the compound provided by the embodiment of the invention has better CGRP protein binding activity, which indicates that the compound provided by the embodiment of the invention can better target CGRP protein to exert a therapeutic effect.
Test example 2: CGRP antagonism assay of Compounds in SK-N-MC cells
SK-N-MC cells were washed 2 times with 250. Mu.l of incubation buffer (pH 7.4) and pre-incubated for 15min at 37 ℃. At increasing concentrations (10) -11 M to 10 -6 M) after addition of CGRP (10 μl) as agonist or an additional 3 to 4 different concentrations of substance, the mixture was incubated for an additional 15 minutes. Intracellular cAMP was then extracted by adding 20. Mu.l of 1M HCl and centrifuging (2000 Xg, 4 ℃ C., 15 min). The supernatant was frozen in liquid nitrogen and stored at-20 ℃. The cAMP content of the samples is determined by radioimmunoassay (Messrs. Amersham) and the pA2 value of the antagonistic substance is determined graphically. In the in vitro test model, the compounds of the invention were found to be in the form of a complex of formula 10 -12 M and 10 -4 The CGRP-antagonistic properties were shown in the dose range between M. K obtained according to the test procedure described above i Values.
| Compounds of formula (I) | Ki(nM) |
| Example 1 Compounds | 4.3 |
| BHV-3100 | 28.6 |
From the above table, the activity of the compound of the embodiment of the invention is 4.3nM, which is obviously superior to that of the positive control drug BHV-3100, and has better CGRP-antagonistic activity.
Test example 3: pharmacokinetic experiments of Compounds
Experimental apparatus and materials
High-speed refrigerated centrifuge, vortex shaker (Vortex Genius 3), high-speed centrifuge (Eppendorf 5415D), disposable syringe, pipette (Eppendorf), SD male rats used in the experiments were all purchased from university of dulcimer, EDTA-K2 vacuum blood collection tube, physiological saline. All oral rats were fasted for 12 hours prior to dosing, were free to drink water, and were fed freely during dosing.
(II) Experimental procedure
Example 1 or bozitinib was dissolved using DMSO/solvent/water (10/10/80) to make a clear solution with a dose of 25mg/kg of intranasal compound and 5mg/kg of caudal compound. 0.5mL of blood was continuously taken from the fundus venous plexus into heparin tubes at 2min,10min,30min,1h,2h,3h,5h,8h,12h,16h,24h after tail vein administration, and 0.5mL of heparin tubes were continuously taken from the fundus venous plexus at 5min,15min,30min,1h,2h,3h,5h,8h,12h,16h,24h after intranasal administration. After centrifugation at 8000r for 10min at 4deg.C, the supernatant plasma was taken and stored at-20deg.C for 0.15mL, followed by LC-MS/MS analysis. The data were analyzed by the WinNolin non-compartmental model to obtain key pharmacokinetic parameters.
(III) results of experiments
TABLE 1 pharmacokinetic parameters
The half-life and peak concentration increase of the oral administration of example 1 relative to BHV-3100 clearly effectively improves the administered dose, thereby reducing the toxic side effects of high-dose administration.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (5)
1. Deuterated compounds of deuterated piperidine amide CGRP inhibitors shown in formula I and pharmaceutically acceptable salts thereof,
2. deuterated piperidine amides and their pharmaceutically acceptable salts according to claim 1, characterized in that the pharmaceutically acceptable salts are selected from the group of mesylate, maleate, hydrochloride or phosphate.
3. Use of deuterated piperidine amides and pharmaceutically acceptable salts thereof according to claim 1 for the preparation of a medicament for the treatment of migraine.
4. The pharmaceutical composition of deuterated piperidine amide compounds and pharmaceutically acceptable salts thereof according to claim 1, wherein the pharmaceutical composition consists of deuterated piperidine amide compounds and pharmaceutically acceptable salts thereof as active ingredients and pharmaceutically acceptable carriers.
5. The pharmaceutical composition of deuterated piperidine amide-based CGRP inhibitor of claim 4 wherein the pharmaceutical composition is selected from the group consisting of capsules, powders, tablets, granules, pills, injections, syrups, oral liquids, inhalants, ointments, suppositories, and patches.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211601118.0A CN116023391A (en) | 2022-12-13 | 2022-12-13 | Deuterated piperidine amide CGRP inhibitor medicine and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211601118.0A CN116023391A (en) | 2022-12-13 | 2022-12-13 | Deuterated piperidine amide CGRP inhibitor medicine and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116023391A true CN116023391A (en) | 2023-04-28 |
Family
ID=86075131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211601118.0A Pending CN116023391A (en) | 2022-12-13 | 2022-12-13 | Deuterated piperidine amide CGRP inhibitor medicine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116023391A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473465A (en) * | 2015-10-30 | 2018-08-31 | 赫普塔瑞斯医疗有限公司 | CGRP receptor antagonist |
-
2022
- 2022-12-13 CN CN202211601118.0A patent/CN116023391A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108473465A (en) * | 2015-10-30 | 2018-08-31 | 赫普塔瑞斯医疗有限公司 | CGRP receptor antagonist |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110831945B (en) | 11, 13-modified saxitoxins for the treatment of pain | |
| JP5756961B2 (en) | Oxyntomodulin analog | |
| CN108699078A (en) | The solid form and preparation method thereof of Thienopyrimidine diketone A CC inhibitor | |
| US5935963A (en) | Piperazinones, their production and use | |
| JP2002516309A (en) | Novel VLA-4 inhibitor: oMePUPA-V | |
| JP6929881B2 (en) | New β-lactamase inhibitor | |
| CN1088708C (en) | Amidine derivatives useful as anti-platelet aggreation inhibitors and vasodilators | |
| WO2024040768A1 (en) | 5-pyridine-1h-indazole compound, pharmaceutical composition, and use | |
| JPS5843982A (en) | Ergot peptide alkaloids, manufacture and medicinal composition | |
| CA3217317A1 (en) | Compounds | |
| EP1512679B1 (en) | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | |
| CN116675680B (en) | Deuterated compound and preparation method, medicine and application thereof | |
| EP3978484A1 (en) | Heteroaromatic acetamide derivative, and preparation and use thereof | |
| CN116023391A (en) | Deuterated piperidine amide CGRP inhibitor medicine and application thereof | |
| CN110372557B (en) | Cyclohexanamines D3/D2Partial receptor agonists | |
| JPH08502057A (en) | Heterocyclic amines with calmodulin-antagonistic properties | |
| EP3722286A1 (en) | Salt of phenylpropionamide derivative and preparation method therefor | |
| CA3239813A1 (en) | Crystal forms of thienoimidazole compound and preparation method thereof | |
| CN104302648B (en) | The crystal form of succinate | |
| US20240166690A1 (en) | Multi-target cyclopeptide molecule for opioid/neuropeptide ff receptors, and preparation therefor and application thereof | |
| CN115385899A (en) | Deuterated drug of ROCK2 inhibitor belumosudil and application thereof | |
| CN107573322A (en) | Imatinib dinitrogen oxide, preparation method and use | |
| US11613547B2 (en) | G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment | |
| CN116496280B (en) | Deuterated acrylamide JAK3 inhibitor medicine and application thereof | |
| CN116496361B (en) | Deuterated mimetic peptide GIP and GLP-1 dual-receptor agonist drug and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |